"10.1371_journal.pone.0034611","plos one","2012-04-12T00:00:00Z","Diane Thomas; John Naughton; Christopher Cote; Susan Welkos; Marianne Manchester; John A T Young","Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America; Nomis Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, California, United States of America; Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland, United States of America","Conceived and designed the experiments: DET JN CC SW JATY MM. Performed the experiments: DET JN CC MM. Analyzed the data: DET JN CC SW JATY MM. Contributed reagents/materials/analysis tools: DET JN CC SW JATY MM. Wrote the paper: DET JN CC SW JATY MM.","JATY is a scientific founder of Pharmathene, Inc. MM and JATY hold stock in Pharmathene, Inc. Pharmathenes product portfolio related to anthrax includes * SparVaxâ¢ - recombinant protective antigen (rPA) anthrax vaccine, and * ValortimÂ® - fully human monoclonal antibody antitoxin â€ treatment of anthrax. JATY and MM have a US patent Appl. No.: 12/070,384, Antitoxin and vaccine platform based on nodavirus VLPs. JATY has US patent application 11/340,424, Anthrax antitoxins. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","04","Diane Thomas","DT",6,TRUE,6,4,6,6,TRUE,TRUE,FALSE,0,NA,FALSE
